By HealthDataConsortium.org Research Team
If you’ve compared CBD products across formats, you’ve probably noticed something odd: a bottle of oil, a jar of gummies, and a blister pack of capsules can all list “25 mg of CBD” and still represent different amounts of CBD actually reaching your bloodstream. That’s not a simple labeling error — it’s a structural problem with comparing formulations at all. This piece walks through why the comparison is harder than it looks, and what questions are worth asking before treating any two CBD products as equivalent.
Why Formulations Complicate the Comparison
The core issue is that “milligrams of CBD on the label” and “milligrams of CBD your body actually absorbs” are not the same number — and how big that gap is depends on format, individual physiology, and even whether the product is taken with food.
Here’s where the science is more limited than it might seem. A 2018 systematic review in Frontiers in Pharmacology (Millar et al.) searched the entire published human literature on CBD pharmacokinetics and found that only one study had ever directly measured CBD’s absolute bioavailability in humans: a 1986 trial on smoked CBD, which came out to 31%. Despite CBD’s oral and sublingual products being the most common formats on the market, the review found no study has directly measured the absolute bioavailability of oral or sublingual CBD in humans. The widely repeated “13–19% oral bioavailability” figure you’ll see on product pages and blogs traces back to older work cited in the review’s introduction, not to a verified human measurement from the review’s own systematic search. That doesn’t mean oral absorption isn’t lower than smoked or inhaled absorption — it almost certainly is — but a precise percentage for oil, gummies, or capsules specifically isn’t something the current human research actually nails down.
What the review’s data do show is that absorption speed and extent vary by formulation in ways that don’t map neatly onto “oil vs. gummy vs. capsule” as categories. One trial in the review compared a reformulated oral capsule (using absorption-enhancing technology) against an oromucosal spray at the same 10 mg dose, and the capsule produced a higher peak blood concentration and greater overall absorption than the spray — the opposite of what a simple “sublingual beats oral” assumption would predict. Another finding that applies across formats: taking CBD with food increased peak concentration and total absorption several-fold compared to a fasted state in one trial. Both points matter for format comparisons, because they show absorption depends more on the specific formulation and how it’s taken than on the oil/gummy/capsule label alone.
Why Ingredient Amounts Aren’t Proof of Comparable Exposure
Absorption differences are only half the problem. The other half is that the labeled amount frequently isn’t the actual amount.
A 2017 study in JAMA (Bonn-Miller et al.) tested 84 CBD products purchased online — primarily oils, tinctures, and vaporization liquids — and found labeling accuracy varied significantly by product type. Oils were the most likely to be labeled accurately in that sample; vaporization liquids were the most frequently mislabeled. Across the full sample, a meaningful share of products contained notably more or less CBD than the label stated. A separate 2022 study in JAMA Network Open (Vandrey et al., Johns Hopkins), testing 105 topical CBD products, found that of the 85% of products that listed a CBD amount at all, most deviated from that labeled value — in-store products averaged 21% more CBD than advertised, online products averaged 10% more, and accuracy varied widely product to product.
Neither study tested capsules or gummies specifically, and topicals aren’t the same product category as ingestibles — so these findings shouldn’t be read as a direct verdict on any specific gummy or capsule product today. What they do establish is a documented pattern of label-to-content mismatch in this broader product category. That matters for format comparisons because a reader comparing “25 mg of oil” to “25 mg of gummy” is comparing two numbers that may each have an unverified relationship to what’s actually in the bottle or jar.
Why There’s No Regulatory Backstop Standardizing This
Part of why this variability persists is regulatory status. The FDA has concluded that CBD and THC are excluded from the legal definition of a dietary supplement, meaning CBD oil, gummies, and capsules sold as supplements or wellness products are not reviewed by FDA for dosage accuracy, manufacturing consistency, or interaction risk before reaching shelves. The agency has approved exactly one CBD drug product — Epidiolex, for specific seizure conditions, available by prescription only. Everything else in the CBD oil/gummy/capsule category exists outside that premarket review process, which is also why FDA has issued warning letters to CBD sellers over unsubstantiated claims rather than enforcing dosage accuracy the way it does for an approved drug.
In practical terms: no regulatory body is independently confirming that the number on any given label reflects the product’s actual content, in any format.
Risks That Differ by Format, Not Just by Dose
Formulation differences also carry different incidental risks that have nothing to do with absorption or labeling accuracy. The CDC notes that cannabis edibles, as a category, carry a distinct risk profile compared to other delivery methods, including a greater risk of unintentional poisoning — particularly because some edible products use packaging that resembles familiar snack or candy branding, which raises the risk of accidental ingestion by children. That risk is specific to the edible/gummy format and doesn’t apply the same way to oil or capsules, which is another reason format isn’t a cosmetic choice layered on top of an otherwise identical product — it changes the risk picture too.
Evidence Worksheet: Questions to Bring to Any CBD Format Comparison
Before treating any side-by-side CBD comparison — including ones you find elsewhere — as settled, it’s worth running it through a short evidence check.
Absorption & Bioavailability
- Observed context: A claim that one format “absorbs better” or “works faster” than another.
- Source type: Is it a specific human pharmacokinetic study, or a general statement with no citation?
- Evidence limit: Direct, absolute bioavailability measurements in humans are missing for most CBD routes — including oral and sublingual, the two most common consumer formats.
- Unresolved question: Is the claim describing a measured percentage, or an assumption based on how the route is generally expected to behave?
- Next-step prompt: Look for the original study rather than a product page’s summary of it, and check whether it measured absorption directly or only inferred it.
Label Accuracy
- Observed context: A product’s stated CBD content in milligrams.
- Source type: A third-party Certificate of Analysis (COA) from an independent lab, or only the manufacturer’s own stated figure?
- Evidence limit: Published label-accuracy testing so far has covered oils, vaporization liquids, and topicals — not gummies or capsules specifically, so format-specific accuracy data for those two categories is currently thin.
- Unresolved question: Is the COA batch-matched to the product you’re holding, and is the testing lab independent of the seller?
- Next-step prompt: Check whether the COA includes a batch or lot number that matches the packaging.
Regulatory Oversight
- Observed context: A claim implying FDA approval, clinical testing, or regulatory backing for a specific CBD oil, gummy, or capsule.
- Source type: A direct FDA approval record, or an inferred/implied claim with no FDA citation.
- Evidence limit: Outside of Epidiolex, no CBD oil, gummy, or capsule marketed as a supplement or wellness product has FDA premarket approval.
- Unresolved question: Is the product marketed in a way that implies a regulatory status it doesn’t actually have?
- Next-step prompt: Search the FDA’s warning letter database for the brand name before assuming regulatory silence means compliance.
Format-Specific Risk
- Observed context: Whether a comparison accounts for risks specific to one format — like edible packaging and accidental ingestion — rather than treating all formats as risk-equivalent.
- Source type: Public health guidance (CDC, FDA) versus general wellness content.
- Evidence limit: Most format-specific risk data concerns accidental exposure and labeling, not comparative long-term health outcomes by format.
- Unresolved question: Does the source distinguish “this format carries different risks” from “this format is medically safer or riskier overall”?
- Next-step prompt: If children or pets are in the household, that factor alone may outweigh any absorption-rate difference between formats.
Running a comparison through these four questions won’t tell you which format is “better” — that depends on individual factors this worksheet doesn’t cover, including existing health conditions and medications, which is a conversation for a healthcare provider rather than a product comparison. What it will do is separate claims backed by something checkable from claims backed only by confident phrasing.
The Bottom Line
“CBD oil vs. gummies vs. capsules” isn’t a single-answer question, and most sources that frame it that way skip the part where format affects both how much CBD actually reaches your bloodstream and what the label’s number is likely to mean. The honest starting point: human bioavailability data for oral and sublingual CBD specifically is thinner than marketing suggests, label accuracy has been documented to vary by product type in independent testing, and none of it is backstopped by FDA premarket review the way an approved drug would be. If you’re also researching THC exposure and detection — a related but separate topic — our guide to THC detox products and detection windows covers that ground in detail.
This article is for educational purposes only and does not constitute medical advice. Consult a healthcare provider before starting or changing any CBD regimen, particularly if you take other medications or have an existing health condition.
